An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
复制标题
DOI：
10.3109/10428194.2013.879713
复制
发表时间：
2014-11-01
影响因子：
2.6
通讯作者：
Jeon, Yoon Kyung
中科院分区：
文献类型：
--
作者：
Nam, Soo Jeong;Go, Heounjeong;Jeon, Yoon Kyung
肿瘤相关巨噬细胞（TAM）和调节性T细胞（TCFs）在肿瘤微环境中起着重要作用。在这里，我们研究了TAMs和Tclad在165弥漫性大B细胞淋巴瘤（DLBCL）的预后意义，使用免疫组织化学。对接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松（R-CHOP）治疗的109例DLBCL进行生存分析。CD 68（+）细胞的增加与总生存期（OS）的改善相关（p = 0.033）。相比之下，CD 163（+）细胞数量增加和CD 163/CD 68（+）细胞比率较高与OS（p = 0.041和0.003）和无进展生存期（PFS）（p < 0.001和0.002）较短显著相关。甲状腺激素升高的患者预后较好。在多变量分析中，CD 163/CD 68（+）细胞比率增加是OS和PFS缩短的独立预测因素。这些结果表明，M2巨噬细胞可能在DLBCL中具有淋巴瘤促进功能，并预测不良的临床结局。靶向M2巨噬细胞的治疗方法对于R时代DLBCL的管理将是有价值的。
Tumor-associated macrophages (TAMs) and regulatory T-cells (Tregs) play an important role in the tumor microenvironment. Here, we investigated the prognostic implications of TAMs and Tregs in 165 diffuse large B-cell lymphomas (DLBCLs) using immunohistochemistry. Survival analysis was performed among 109 DLBCLs treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). An increase in CD68 (+) cells was related to improved overall survival (OS) (p = 0.033). By contrast, an increased number of CD163 (+) cells and a higher ratio of CD163/CD68 (+) cells were significantly associated with shorter OS (p = 0.041 and 0.003) and progression-free survival (PFS) (p < 0.001 and 0.002). Patients with increased Tregs tended to have a better prognosis. In multivariate analysis, an increased ratio of CD163/CD68 (+) cells was an independent predictor of shorter OS and PFS. These results suggest that M2 macrophages might have a lymphoma-promoting function in DLBCL and predict poor clinical outcome. Therapeutic approaches targeting M2 macrophages would be valuable for the management of DLBCL in the R era.